Market Closed -
OTC Markets
12:10:54 2024-04-30 pm EDT
5-day change
1st Jan Change
72.5
USD
-3.33%
-.--%
+13.28%
BIOQUAL Declares Dividend Payable on October 21, 2020
September 15, 2020 at 10:52 am EDT
BIOQUAL's Board of Directors has declared a dividend of $1.10 per share for shareholders of record on September 28, 2020, payable on October 21, 2020.
Bioqual, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023
Jan. 23
CI
Bioqual, Inc. Reports Earnings Results for the First Quarter Ended August 31, 2023
23-10-20
CI
Bioqual, Inc. Reports Earnings Results for the Full Year Ended May 31, 2023
23-09-21
CI
Bioqual, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023
23-04-21
CI
Bioqual, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2022
23-01-20
CI
Bioqual, Inc. Reports Earnings Results for the First Quarter Ended August 31, 2022
22-10-21
CI
Bioqual, Inc. Appoints Charles C. Kirk, Jr., CPA as Chief Financial Officer
22-10-05
CI
BIOQUAL Declares Dividend, Payable on October 27, 2022
22-09-27
CI
Bioqual, Inc. Reports Earnings Results for the Full Year Ended May 31, 2022
22-09-19
CI
BIOQUAL, Inc. Adds Dave Newcomer to its Board
22-05-09
CI
BIOQUAL, Inc. Announces Retirement of Dave Newcomer as Chief Financial Officer, Effective June 3, 2022
22-05-09
CI
BIOQUAL, Inc. Appoints Hanne Andersen Elyard as Chief Scientific Officer
22-05-09
CI
Earnings Flash (BIOQ) BIOQUAL Posts Q3 Revenue $17.1M
22-04-21
MT
Bioqual, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2022
22-04-21
CI
Bioqual, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2021
22-01-21
CI
Bioqual, Inc. Reports Earnings Results for the First Quarter Ended August 31, 2021
21-10-22
CI
Bioqual, Inc. Reports Earnings Results for the Full Year Ended May 31, 2021
21-09-17
CI
BIOQUAL, Inc. Declares Dividend, Payable on October 20, 2021
21-09-17
CI
Bioqual, Inc. Reports Earnings Results for the Third Quarter Ended February 28, 2021
21-04-21
CI
Bioqual, Inc. Announces Publication of an Investigational COVID-19 Vaccine Candidate
20-09-21
CI
Bioqual, Inc. Reports Earnings Results for the Full Year Ended May 31, 2020
20-09-16
CI
BIOQUAL Declares Dividend Payable on October 21, 2020
20-09-15
CI
BIOQUAL Announces Release of Two COVID-19 Research Publications
20-05-20
CI
Bioqual, Inc. Reports Earnings Results for the Third Quarter Ended February 29, 2020
20-04-21
CI
BIOQUAL Announces COVID-19 Vaccine Testing
20-03-31
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. It also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.
More about the company
1st Jan change
Capi.
+13.28% 64.85M +0.17% 42.19B +10.92% 42.24B +44.30% 40.15B -6.20% 28.31B +5.23% 24.63B -24.79% 18.2B +26.69% 12.01B -3.13% 11.76B +6.57% 10.4B
Other Biotechnology & Medical Research
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
BIOQUAL, INC. 
